Related Experiment Video
Updated: May 31, 2026
12:44
The In ovo CAM-assay as a Xenograft Model for Sarcoma
Published on: July 17, 2013
Advances in sarcoma genomics and new therapeutic targets
Barry S Taylor1, Jordi Barretina, Robert G Maki
1Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.
Nature Reviews. Cancer
|July 15, 2011
Summary
This review explores molecular drivers of sarcoma development. It highlights how genomic and genetic insights, alongside new therapies, could revolutionize sarcoma patient care.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Human mesenchymal malignancies, particularly sarcomas, are increasingly classified by their underlying pathogenetic abnormalities.
- Despite identification of prevalent molecular aberrations in specific sarcoma subtypes, targeted therapeutic options remain limited.
- Current sarcoma treatment often relies on traditional modalities, with frequent resistance to adjuvant therapies.
Purpose of the Study:
- To review the core molecular determinants driving sarcomagenesis.
- To emphasize emerging genomic and functional genetic approaches in sarcoma research.
- To discuss novel therapeutic strategies for transforming sarcoma patient care.
Main Methods:
- Literature review focusing on molecular determinants of sarcomagenesis.
- Analysis of emerging genomic and functional genetic studies.
- Synthesis of current and novel therapeutic strategies for sarcoma.
Main Results:
- Sarcomagenesis is driven by specific molecular abnormalities, though many are not therapeutically targeted.
- Genomic and functional genetic studies are revealing key insights into sarcoma development.
- Novel therapeutic strategies are emerging based on these molecular insights.
Conclusions:
- Understanding molecular drivers is crucial for classifying and treating sarcomas.
- Genomic and genetic approaches offer new avenues for therapeutic development in sarcoma.
- Integrated strategies combining molecular insights and novel therapies hold promise for improving sarcoma patient outcomes.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...